Insulet Corporation which can be found using ticker (PODD) have now 18 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $270.00 and $163.00 and has a mean target at $215.06. Now with the previous closing price of $181.26 this indicates there is a potential upside of 18.6%. Also worth taking note is the 50 day moving average now sits at $154.13 and the 200 moving average now moves to $249.30. The company has a market cap of 12.66B. The stock price for the company is currently is currently $181.32 USD
The potential market cap would be $15,022,094,624 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 105.42, revenue per share of $22.35 and a 2.36% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
